1 / 6

Search strategy and results

Search strategy and results. Amir Kashani, et al. Circulation. 2006;114:2788-2797. Baseline Characteristics. CHD indicates coronary heart disease; DM, diabetes mellitus; PMSG, Pravastatin Multinational Study Group; SSSS, Scandinavian Simvastatin Survival Study; HPS,

chibale
Download Presentation

Search strategy and results

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Search strategy and results Amir Kashani, et al. Circulation. 2006;114:2788-2797

  2. Baseline Characteristics CHD indicates coronary heart disease; DM, diabetes mellitus; PMSG, Pravastatin Multinational Study Group; SSSS, Scandinavian Simvastatin Survival Study; HPS, Heart Protection Study; and NR, not reported. Two studies randomized patients to 2 different statins. *Defined as other relevant cardiovascular diseases. †Numbers represent combined mean for statin and placebo arms of the study. ‡History of hypertension indicates patients on antihypertensive therapy at time of study inclusion. §History of DM indicates history of non–insulin-dependent DM. Represents current or former smokers. ¶History of smoking indicates cigarette smoking. #All patients had a history of angina or history of myocardial infarction. **History of hypertension and history of DM indicates treated hypertension and treated DM. ††Numbers based on table/figure in study. Amir Kashani, et al. Circulation 2006;114:2788-2797

  3. Study Characteristics NR indicates not reported *No. of patients randomized to this dose was not reported †Frequency of testing laboratory data ‡Six-wk intervals for 1 y, then 12-wk intervals. §Every 6 weeks for 15 months, then quarterly. Every 6 weeks for 18 months, then every 24 weeks. Amir Kashani, et al. Circulation 2006;114:2788-2797

  4. Risk Difference of Various End Points Associated With Currently FDA-Approved Statins Amir Kashani, et al. Circulation 2006;114:2788-2797

  5. Cerivastatin Trials Amir Kashani, et al. Circulation. 2006;114:2788-2797

  6. Risk difference of FDAapproved statins vs cerivastatin Amir Kashani, et al. Circulation. 2006;114:2788-2797

More Related